Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Scientific Officer | July 28, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 34,000 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 51,000 · Balance 85,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 51,000 · Balance 34,000 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 51,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 85,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 85,000 RSUs reported in Table I (34,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 85,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 85,000 RSUs reported in Table I (34,000 RSUs) are subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 31, 2026 00:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionRestricted Stock Units · Derivative | 51,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003417 · form4.xml · derivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 51,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 85,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3 · derivative.exercise_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 85,000 RSUs reported in Table I (34,000 RSUs) are subject to vesting. F3 · derivative.expiration_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 85,000 RSUs reported in Table I (34,000 RSUs) are subject to vesting. Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerOrdinary Shares, par value $0.01 per share | 51,000 | $8.56 | $436,560.00 |
DisclosureSEC source: 0000905148-26-003417 · form4.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 51,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-003417 · form4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:51 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0000905148-26-001182 · form4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Ordinary Shares · 190,000 shares Expires 2036-03-03 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:52 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantOrdinary Shares, par value $0.01 per share | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002662 · form4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:51 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 107,500 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0000905148-25-000890 · form4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,500 Underlying: Ordinary Shares · 107,500 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 02:11 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $30.30 | $0.00 |
DisclosureSEC source: 0000905148-24-000841 · form4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 85,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 01:00 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001140361-23-037713 · form4.xml · derivative · entry 4 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,000 Underlying: Ordinary Shares · 4,000 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 25, 2021, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 01:00 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 229 | $68.07 | $15,588.63 |
DisclosureSEC source: 0001140361-23-037713 · form4.xml · nonDerivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $67.92 to $68.39, inclusive. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 01:00 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,771 | $66.98 | $252,592.89 |
DisclosureSEC source: 0001140361-23-037713 · form4.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $66.495 to $67.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 01:00 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $12.15 | $48,600.00 |
DisclosureSEC source: 0001140361-23-037713 · form4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001140361-23-033192 · form4.xml · derivative · entry 4 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,000 Underlying: Ordinary Shares · 4,000 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 25, 2021, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,009 | $68.69 | $69,305.59 |
DisclosureSEC source: 0001140361-23-033192 · form4.xml · nonDerivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $68.44 to $68.995, inclusive. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,991 | $67.98 | $203,342.24 |
DisclosureSEC source: 0001140361-23-033192 · form4.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,009 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $67.385 to $68.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 01:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $12.15 | $48,600.00 |
DisclosureSEC source: 0001140361-23-033192 · form4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · derivative · entry 8 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,000 Underlying: Ordinary Shares · 4,000 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 25, 2021, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $29.81 | $0.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · derivative · entry 7 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares subject to the option have fully vested. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 294 | $73.14 | $21,503.16 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 6 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,759 | $71.96 | $270,479.22 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 5 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 294 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $71.57 to $72.41, inclusive. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 12,004 | $70.99 | $852,180.77 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 4 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,053 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $70.545 to $71.4925, inclusive. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,943 | $70.02 | $206,060.91 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,057 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $69.54 to $70.53, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $12.15 | $48,600.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,000 | $29.81 | $447,150.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $52.97 | $0.00 |
DisclosureSEC source: 0001140361-23-010184 · form4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2033-03-02 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 2, 2024 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $32.45 | $0.00 |
DisclosureSEC source: 0001140361-22-006897 · form4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 85,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 23, 2023 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 81,250 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · derivative · entry 10 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 Underlying: Ordinary Shares · 81,250 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $27.81 | $0.00 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · derivative · entry 9 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,000 shares Expires 2025-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The shares subject to the option were fully vested as of the date of the exercise. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $20.17 | $0.00 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · derivative · entry 8 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2023-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The shares subject to the option were fully vested as of the date of the exercise. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,203 | $49.01 | $254,985.50 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · nonDerivative · entry 7 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $48.31 to $49.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 18,101 | $47.81 | $865,497.50 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · nonDerivative · entry 6 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,203 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $47.31 to $48.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 26,106 | $46.27 | $1,208,036.88 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · nonDerivative · entry 5 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,304 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $46.03 to $46.89, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 65,840 | $45.42 | $2,990,248.70 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · nonDerivative · entry 4 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,410 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $45.015 to $46.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 81,250 | $15.04 | $1,222,000.00 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · nonDerivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 19,000 | $27.81 | $528,390.00 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,000 | $20.17 | $302,550.00 |
DisclosureSEC source: 0001567619-21-012571 · doc1.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 22:08 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $22.60 | $0.00 |
DisclosureSEC source: 0001567619-21-005077 · doc1.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Ordinary Shares · 56,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 23:39 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,540 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-21-004526 · doc1.xml · derivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,540 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The shares subject to the option were fully vested as of the date of the exercise. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 23:39 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 7,540 | $25.50 | $192,270.00 |
DisclosureSEC source: 0001567619-21-004526 · doc1.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 23:39 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 7,540 | $6.41 | $48,331.40 |
DisclosureSEC source: 0001567619-21-004526 · doc1.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:47 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0001567619-21-004318 · doc1.xml · derivative · entry 6 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Ordinary Shares · 18,750 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:47 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,560 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-21-004318 · doc1.xml · derivative · entry 5 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540 Underlying: Ordinary Shares · 7,560 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The original grant was for 36,000 shares, of which 28,460 shares have been exercised and sold. The remaining shares underlying the option (7,540 shares) are fully vested and exercisable as of the date hereof. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:47 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 18,750 | $20.00 | $375,007.50 |
DisclosureSEC source: 0001567619-21-004318 · doc1.xml · nonDerivative · entry 4 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.00 to $20.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:47 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 18,750 | $13.53 | $253,687.50 |
DisclosureSEC source: 0001567619-21-004318 · doc1.xml · nonDerivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:47 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 7,560 | $17.07 | $129,049.20 |
DisclosureSEC source: 0001567619-21-004318 · doc1.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:47 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 7,560 | $6.41 | $48,459.60 |
DisclosureSEC source: 0001567619-21-004318 · doc1.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:17 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001567619-20-005019 · doc1.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Ordinary Shares · 70,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2021 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005425 · doc4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017932 · doc4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0000899243-18-005297 · doc4.xml · derivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2028-02-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 900 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0000899243-17-022966 · doc4.xml · derivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,100 Underlying: Ordinary Shares · 900 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The original grant was for 36,000 shares, of which 20,000 shares have been exercised and sold. The remaining shares underlying the option (15,100 shares) are fully vested and exercisable as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.